

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/562,478
Filing Date	11-15-2006
First Named Inventor	Gordana Kosutic
Group Art Unit	1656
Examiner Name	Liu, Samuel

Sheet 1 of 1 Attorney Docket Number 014811-487.114

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
	3,256,153			Heimlich	6-14-1966
	3,868,356			Smyth	2-25-1975
	3,919,411			Glass et al.	11-11-1975
	3,950,517			Lindsay et al.	4-13-1976
	4,003,792			Mill et al	1-18-1977
	4,044,196			Hupel et al	8-23-1977
	4,087,390			Shields	5-2-1978
	4,093,574			Shields	6-6-1978
	4,100,117			Shields	7-11-1978
	4,179,337			Davis et al	12-18-1979
	4,223,163			Guilloty	9-16-1980
	4,229,438			Fujino et al	10-21-1990
	4,253,998			Sarantakis	3-3-1981
	4,277,394			Fujino et al	7-7-1981
	4,338,306			Kitao et al	7-6-1982
	4,348,387			Brownlee et al	9-7-1982
	4,410,547			Ueno et al	10-18-1983
	4,459,681			Brownlee et al	9-4-1984
	4,472,392			Labrie et al	9-16-1984
	4,526,938			Churchill et al	7-2-1985
	4,544,101			Hopp	11-19-1985
	4,579,730			Kidron et al	4-1-1986
	4,585,754			Meissner et al	4-29-1986
	4,662,392			Vadasz	5-5-1987
	4,684,524			Eckenhoff et al	8-4-1987
	4,698,264			Steinke	10-6-1987
	4,717,566			Eckenhoff et al	1-5-1988
	4,772,471			Vanlerberghe et al	9-20-1988
	4,774,976			Vanlerberghe et al	10-4-1988
	4,797,288			Sharma et al	1-10-1989
	4,801,575			Pardridge	1-31-1989
	4,839,341			Massey et al	6-13-1989
	4,840,799			Applegren et al	6-20-1989
	4,849,405			Ecanow	7-18-1989
	4,917,888			Katre et al	4-17-1990
	4,935,246			Ahrens	6-19-1990
	4,946,828			Markussen	8-7-1990
	4,957,910			Sutton et al	9-18-1990
	4,963,367			Ecanow	10-16-1990
	4,963,526			Ecanow	10-16-1990
	4,994,439			Longenecker et al	2-19-1991
	5,013,556			Woodle et al	5-7-1991
	5,055,300			Gupta	10-8-1991
	5,055,304			Makino et al	10-8-1991
	5,089,261			Nitecki et al	2-18-1992
	5,093,198			Speaker et al	3-3-1992
	5,099,074			Mueller et al	3-24-1992
	5,108,568			Van Alestine	4-28-1992

TRU 676491 v1

/Samuel Liu/

Date Considered

10/25/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.L./

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	2	Attorney Docket Number	014811-487.114
-------	---	------------------------	----------------

<i>Complete if Known</i>			
Application Number	10/562,478		
Filing Date	11-15-2006		
First Named Inventor	Gordana Kosutic		
Group Art Unit	1656		
Examiner Name	Liu, Samuel		

TRU-676491.v1

/Samuel Liu/

Date Considered

10/25/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.L./

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

		<i>Complete if Known</i>	
Application Number	10/562,478		
Filing Date	11-15-2006		
First Named Inventor	Gordana Kosutic		
Group Art Unit	1656		
Examiner Name	Liu, Samuel		
Sheet	3	Attorney Docket Number	014811-487.114

5,707,648	Yiv	1-13-1998
5,714,639	Bowman et al	2-3-1998
5,738,846	Greenwald et al	4-14-1998
5,747,445	Backstrom et al	5-5-1998
5,747,642	De Felippis	5-5-1998
5,750,497	Havelund et al	5-12-1998
5,763,396	Weiner et al	6-9-1998
5,766,620	Heiber et al	6-16-1998
5,773,581	Camble et al	6-30-1998
5,824,638	Burnside et al	10-20-1998
5,830,853	Backstrom et al	11-3-1998
5,830,918	Sportsman et al	11-3-1998
5,843,866	Parker et al	12-1-1998
5,849,860	Hakimi et al	12-15-1998
5,853,748	New	12-29-1998
5,854,208	Jones et al	12-29-1998
5,856,451	Olsen et al	1-5-1999
5,866,538	Norup et al	2-2-1999
5,866,584	Cincotta et al	2-2-1999
5,874,111	Maitra et al	2-23-1999
5,898,028	Jensen et al	4-27-1999
5,902,568	Greenwald et al	5-11-1999
5,905,140	Hansen	5-18-1999
5,907,030	Shen et al	5-25-1999
5,922,675	Baker et al	7-13-1999
5,932,462	Harris et al	8-3-1999
5,942,248	Barnwell	8-24-1999
5,948,751	Kimer et al	9-7-1999
5,952,008	Backstrom et al	9-14-1999
5,952,297	De Felippis et al	9-14-1999
5,962,267	Shin et al	10-5-1999
5,966,549	New et al	10-19-1999
5,969,040	Hallahan et al	10-19-1999
5,981,709	Greenwald et al	11-9-1999
5,985,283	Lee et al	11-16-1999
6,004,574	Backstrom et al	12-21-1999
6,011,008	Domb et al	1-4-2000
6,025,325	Campfield et al	2-15-2000
6,034,054	De Felippis et al	3-7-2000
6,042,822	Gilbert et al	3-28-2000
6,043,214	Jensen et al	3-28-2000
6,051,551	Hughes et al	4-18-2000
6,057,292	Cunningham et al	5-2-2000
6,063,761	Jones et al	5-16-2000
6,093,391	Kabanov et al	7-25-2000
6,113,906	Greenwald et al	9-5-2000
6,165,976	Backstrom et al	12-26-2000
6,177,087	Greenwald et al	1-23-2001
6,191,105	Ekwuribe et al	2-20-2001
6,200,602	Watts et al	3-13-2001
6,211,144	Havelund	4-3-2001

TRU-676491 v1

/Samuel Liu/

Date Considered

10/25/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.L./

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

*Complete if Known*

Application Number	10/562,478
Filing Date	11-15-2006
First Named Inventor	Gordana Kosutic
Group Art Unit	1656
Examiner Name	Liu, Samuel

Sheet 4 Attorney Docket Number 014811-487.114

	6,248,363	Patel et al	6-19-2001
	6,251,856	Markussen et al	6-26-2001
	6,258,377	New et al	7-10-2001
	6,268,335	Brader	7-31-2001
	6,306,440	Backstrom et al	10-23-2001
	6,309,633	Ekwuribe et al	10-30-2001
	6,310,036	Havelund	10-30-2001
	6,323,311	Liu et al	11-27-2001
	6,335,316	Hughes et al	1-1-2002
	6,342,225	Jones et al	1-29-2002
	6,352,974	Ghirm et al	3-5-2002
	6,506,730	Lee et al	1-14-2003
	6,713,452	Ekwuribe et al	3-30-2004
	7,030,062	Soltero et al	4-18-2002
	6,858,580	Ekwuribe et al	2-22-2005
	6,191,105	Ekwuribe et al	2-20-2001
	6,828,297	Ekwuribe et al	2-22-2005

## US Published Applications

Examiner Initials*	Cite No	Publication No	Date	Applicant
		2002/0160938	10-31-2002	Brandenburg et al.
		2003/0004304	1-2-2003	Ekwuribe et al
		2003/0027748	2-6-2003	Ekwuribe et al
		2003/0027995	2-6-2003	Ekwuribe et al
		2003/0050228	3-13-2003	Ekwuribe et al
		2003/0060606	3-27-2003	Ekwuribe et al
		2003/0069170	4-10-2003	Soltero et al
		2003/0083232	5-1-2003	Soltero et al
		2003/0087808	5-8-2003	Soltero et al
		2003/0144468	7-31-2003	Ekwuribe et al
		2003/0153488	8-14-2003	May et al
		2004/0017387	1-29-2004	Soltero et al
		2004/0038867	2-24-2004	Still et al.
		2003/0229009	12-11-2003	Krishnan, Radha
		2004/0038866	2-26-2004	Soltero et al
		2003/0229009	12-11-2003	Soltero et al
		2004/0091452	5-13-2004	Ekwuribe et al

Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number		
			EP 0031567	Masahiko, Fujino	7-8-1981

TRI: 676691 v1

/Samuel Liu/

Date Considered

10/25/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.L./

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

		<i>Complete if Known</i>	
Application Number	10/562,478		
Filing Date	11-15-2006		
First Named Inventor	Gordana Kosutic		
Group Art Unit	1656		
Examiner Name	Liu, Samuel		
Sheet	5	Attorney Docket Number	014811-487.114

EP 0092918	A2	Churchill, Jeffrey	11-2-1983
EP 0354855	A2	Yoshida, Hiroshi	2-14-1990
EP 0381070	A1	Butelman, Edoardo	8-8-1990
EP 0483465	B1	Salama et al	8-2-1992
EP 0511903	A2	Wanter, Henry	11-4-1992
EP 0483465		Salama et al	8-6-1995
EP 0597007		Constantinides, Panayiotis	10-16-1996
EP 0621777		Wunderlich et al	11-2-1996
EP 0797615	B1	Coombs et al	1-13-1997
EP 0822218	A2	Miller et al	2-4-1998
GB 1492997		Smyth, Derek G.	11-23-1977
JP 01207320		Motoyuki, Ishikura	8-21-1989
JP 1254699		Muranishi, Shozo	10-11-1989
WO 93/01802		Heimgartner, Frederic	2-4-1993
WO 94/23740		Bentz, Johanna	10-27-1994
WO 95/09831		Del Soldato, Piero	4-13-1995
WO 95/30641		Del Soldato, Piero	11-16-1995
WO 97/14740		Morgan, A.	4-24-1997
WO 98/07745		Fraser, Janet	2-26-1998
WO 99/32134		Lee, Seoju	7-1-1999
WO 99/65941		Jones, Richard	12-23-1999
WO 00/43034		Kingman, NG	7-27-2000
WO 00/78302	A1	Ekwuribe, W.	12-28-2000
WO 01/12230		Park, Myung-ok	2-22-2001
WO 02/09766	A1	Park, Myung-ok	2-22-2001
WO 02/098232	A1	Ekwuribe, W.	12-12-2002
WO 02/098446	A1	Ekwuribe, W	12-12-2002
WO 03/022208	A2	Soltero, Richard	3-20-2003
WO 03/022210	A2	Soltero, Richard	3-20-2003
WO 03/022210	A3	Soltero, Richard	3-20-2003
WO 03/022996	A2	Soltero, Richard	3-20-2003
DE 19632440	A1	Gehrer, Eugen	2-19-1998

TRU 676491 v2

/Samuel Liu/

Date Considered

10/25/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.L./

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6

## Complete if Known

Application Number	10/562,478
Filing Date	11-15-2006
First Named Inventor	Gordana Kosutic
Group Art Unit	1656
Examiner Name	Liu, Samuel

Attorney Docket Number 014811-487.114

## OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
		Banting et al., "Pancreatic Extracts in the Treatment of Diabetes Mellitus," <i>Can. Med. Assoc. J.</i> , 12: 141-146 (1922).	
		Coudert et al., "A Novel, Unequivocal Synthesis of Polyethylene Glycols," <i>Synthetic Communications</i> , 16(1): 19-26 (1986).	
		Francis, G.E., et al., Polyethylene Glycol Modification: Relevance of Improved Methodology to Tumour Targeting, <i>Journal of Drug Targeting</i> , vol. 3, pp. 321-340 (1996).	
		Guzman, Angel, et al., Effects of Fatty Ethers and Stearic Acid of the Gastrointestinal Absorption of Insulin, <i>PRHS</i> , vol. 9, No. 2, pp. 155-159 (Aug. 1990).	
		H. Alcock & F. Lampe, "Contemporary Polymer Chemistry," 394403 (2nd. ed., 1991).	
		J. Milton Harris, "Laboratory Synthesis of Polyethylene Glycol Derivatives," <i>J. Macromol. Science Rev. Macromol. Chem. Phys.</i> , C25(3): 325-373 (1985).	
		Krishnan, B. Radha, et al., Stability and Physical Characteristics of Orally Active Amphiphilic Human Insulin Analog, Methoxy (Polyethylene Glycol) Hexanoyl Human Recombinant Insulin (HIM2), <i>Proceed. Intl. Symp. Control. Rel. Bioact. Mater.</i> , vol. 27 pp. 1038-1039 (2000).	
		Lindsay, D.G., et al., The Acetylation of Insulin, <i>Biochem J.</i> vol. 121, pp. 737-745 (1971).	
		Mesih, M.S., et al., Hypoglycaemic effect of oral insulin preparations containing Brij 35, 52, 58 or 92 and stearic acid, <i>J. Pharm. Pharmacol.</i> , vol. 33, pp. 733-734 (1981).	
		Moghaddam, Amir, Use of polyethylene glycol polymers for bioconjugations and drug development, <i>American Biotechnology Laboratory</i> , pp. 42, 44 (Jul. 2001).	
		Neubauer, H. Paul, et al., Influence of Polyethylene Glycol Insulin on Lipid Tissues of Experimental Animals, <i>Diabetes</i> , vol. 32, pp. 953-958 (Oct. 1983).	
		Shen, Wei-Chiang, et al., (C) Means to Enhance Penetration; (3) Enhancement of polypeptide and protein absorption by macromolecular carriers via endocytosis and transcytosis, <i>Advanced Drug Delivery Reviews</i> , vol. 8, pp. 93-113 (1992).	
		Sirokman, Geza, et al., Refolding and proton pumping activity of a polyethylene glycolbacteriorhodopsin water-soluble conjugate, <i>Protein Science</i> , vol. 2, pp. 1161-1170 (1993).	
		Torchilin, Vladimir P., Immunoliposomes and PEGylated Immunoliposomes: Possible Use for Targeted Delivery of Imaging Agents, <i>Immunomethods</i> , vol. 4, pp. 244-258 (1994).	
		Wei, Jiang, et al., A Poly(Ethylene Glycol) Water-soluble Conjugate of Porin:	

TRU 676491v1

/Samuel Liu/

Date Considered

10/25/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.L./

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

<i>Complete if Known</i>	
Application Number	10/562,478
Filing Date	11-15-2006
First Named Inventor	Gordana Kosutic
Group Art Unit	1656
Examiner Name	Liu, Samuel
Sheet	7
Attorney Docket Number	014811-487.114

	Refolding to the Native State, <i>Biochemistry</i> , vol. 34, pp. 6408-6415 (1995).
	Xia, Jiding, et al., Effects of polyoxyethylene chain length distribution on the interfacial properties of polyethylene glycol n-dodecyl ether, <i>Yinghong Huaxue</i> , vol. 2, No. 4, pp. 59-65 (Abstract Only) (1985).
	Y. Chen & G. Baker, "Synthesis and Properties of AMA Amphiphiles," <i>J. Org. Chem.</i> , 64: 6870-6873 (1999).
	Zalipsky, Samuel, et al., Peptide Attachment to Extremities of Liposomal Surface Grafted PEG Chains: Preparation of the Long-Circulating Form of Laminin Pentapeptide, YIGSR, <i>Bioconjugate Chem.</i> , vol. 6, pp. 705-708 (1995).
	Baudy et al., "Stabilization and intestinal absorption of human calcitonin," <i>Journal of Controlled Release</i> 39: 145-151 (1996).
	Hinds et al., <i>Synthesis and Characterization of Polyethylene glycol)-Insulin</i> , <i>Bioconjugate Chem.</i> , vol. 11, 2000, pp. 195-201.
	Abuchowski, A. and F. F. Davis "Soluble Polymer-Enzyme Adducts" pp. 367-383, <i>Enzymes as Drugs</i> , Ed. J. S. Holcenberg, John Wiley (1981).
	Agarwal et al. "Polymethacrylate-based Microparticulates of Insulin for Oral Delivery: Preparation and In Vitro Dissolution Stability in the Presence of Enzyme Inhibitors" <i>International Journal of Pharmaceutics</i> 225:31-39 (2001).
	Akiyama et al. "The Synthesis of New Derivatives of 1-13-D-Arabinofuranosylcytosine" <i>Chem. Pharm. Bull.</i> 26(3):981-984 (1978).
	Allaudeen et al. "Orally Active Insulin: A Single Insulin Conjugate Selected for Future Studies" 60th Annual Meeting of the American Diabetes Assoc., Atlanta, GA, Jun. 2000 (Abstract).
	Anderson et al. "HIM2, a Novel Modified Insulin, has Improved Systemic Pharmacokinetics in Normal Dogs, Compared to Unmodified Insulin" American Diabetes Association 62nd Annual Meeting, Jun. 2002 (Abstract).
	Ansell et al. "Application of Oligo-(14-amino-3,6,9,12- tetraoxatetradecanoic acid) Lipid Conjugates as Steric Barrier Molecules in Liposomal Formulations" <i>Bioconjugate Chem.</i> 10:653-666 (1999).
	Aoshima et al. "N <sup>4</sup> -Bchenoyl-1-13-D-Arabinofuranosylcytosine as a Potential New Antitumor Agent" <i>Cancer Research</i> 37:2481-2486 (1977).
	Banting et al. "Pancreatic Extracts in the Treatment of Diabetes Mellitus: Preliminary Report" <i>Can. Med. Assoc. J.</i> 145(10):1281-1286 (1991).
	Baudys et al. "Stabilization and Intestinal Absorption of Human Calcitonin" <i>J. Control. Rel.</i> 39:145-151 (1996).
	Baudys et al. "Synthesis and Characterization of Different Glycosylated Derivatives of Insulin" <i>Proceed Intern Symp. Cont. Rd. Bioactive Mater.</i> 19:210-211 (1992).
	Baker, D. C. et al. "Prodrugs of 9-13-D-Arabinofuranosyladenine. I. Synthesis and Evaluation of Some 5-(0 Acyl) Derivatives" <i>J. Med. Chem.</i> 21(12):1218-1221

TRU: 676491 v1

/Samuel Liu/

Date Considered

10/25/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.L./

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

		<i>Complete if Known</i>	
Application Number	10/562,478		
Filing Date	11-15-2006		
First Named Inventor	Gordana Kosutic		
Group Art Unit	1656		
Examiner Name	Liu, Samuel		
Sheet	8	Attorney Docket Number	014811-487.114

	(1978).	
	Boccu et al. "Pharmacokinetic Properties of Polyethylene Glycol Derivatized Superoxide Di smutase" <i>Pharm. Res. Comm.</i> 14:113 -120 (1982).	
	Bone et al. "Successful Treatment of an Insulin Dependent Rat Model of Human Type 1 Diabetes with Orally Active Insulin" Program and Abstracts, 4th International Workshop on Lessons from Animal Diabetes, Omiya, Japan, Nov. 1994 (Abstract).	
	Brange and Volund "Insulin Analogs with Improved Pharmacokinetic Profiles" <i>Advanced Drug Delivery Reviews</i> 35:307335 (1999).	
	Brange et al. "Chemical Stability of Insulin. 1. Hydrolytic Degradation During Storage of Pharmaceutical Preparations" <i>Pharm. Res.</i> 9(6):715-726 (1992).	
	Brange et al. "Chemical Stability of Insulin. 2. Formation of Higher Molecular Weight Transformation Product During Storage of Pharmaceutical Preparations" <i>Pharm. Res.</i> 9(6):727-734 (1992).	
	Brange, J. "Galencies of Insulin: The Physico-Chemical and Pharmaceutical Aspects of Insulin and Insulin Preparations" Novo Research Institute, Denmark, pp. 18-100 (1987).	
	Chien, Y. W., Novel Drug Delivery Systems, pp. 678-679, Marcel Dekker, Inc., New York, N.Y. (1992).	
	Cleland et al. "Emerging Protein Delivery Methods" <i>Current Opinion in Biotechnology</i> 12:212-219 (2001).	
	Clement et al. "Effects of Multiple Doses of Orally Administered Hexyl Insulin M2 (HIM2) on Postprandial Blood Glucose (PPG) Concentrations in Type 1 Diabetic (T1) Patients" American Diabetes Association 62nd Annual Meeting, Jun. 2002 (Poster).	
	Clement et al. "Oral Insulin Product Hexyl-Insulin Monoconjugate 2 (HIM2) in Type 1 Diabetes Mellitus: The Glucose Stabilization Effects of HIM2" <i>Diabetes Technology &amp; Therapeutics</i> 4(4):459-466 (2002).	
	Clement, Stephen "A Dose-Escalation Study of the Effects of Two Sequential Doses of Oral Modified Insulin on Blood Glucose Concentrations in Patients with Type 1 Diabetes Mellitus" American Diabetes Association Annual Meeting (Jun. 25, 2001) (Abstract).	
	Clement, Stephen "A Dose-Escalation Study of the Effects of Two Sequential Doses of Oral Modified Insulin on Blood Glucose Concentrations in Patients with Type 1 Diabetes Mellitus" American Diabetes Association Annual Meeting (Jun. 25, 2001) (Poster).	
	Conradi et al. "The Influence of Peptide Structure on Transport Across Caco-2 Cells" <i>Pharm. Res.</i> 8(12):1453-1459 (1991).	
	Coombes et al. "Biodegradable Polymeric Microparticles for Drug Delivery and Vaccine Formulation: the Surface Attachment of Hydrophilic Species Using the Concept of Poly(Ethylene Glycol) Anchoring Segments" <i>Biomaterials</i> 18:1153 -	

TRU-676491 v1

/Samuel Liu/

Date Considered

10/25/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.L./

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number	10/562,478
Filing Date	11-15-2006
First Named Inventor	Gordana Kosutic
Group Art Unit	1656
Examiner Name	Liu, Samuel

Sheet	9	Attorney Docket Number	014811-487.114
-------	---	------------------------	----------------

	1161 (1997).	
	Damge et al. "Poly(alkyl cyanoacrylate) Nanospheres for Oral Administration of Insulin" <i>Journal of Pharmaceutical Sciences</i> 86(12):1403-1409 (Dec. 1997).	
	Dandona et al. "Effect of an Oral Modified Insulin on Blood Glucose Levels in Fasting and Fed Type 1 Diabetic Patients Receiving a 'Basal' Regimen of Injected Insulin" American Diabetes Association Annual Meeting (Jun. 25, 2001) (Abstract).	
	Delgado et al. "The Uses and Properties of PEG-Linked Proteins" <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> 9(3,4):249304 (1992).	
	Ekwuribe, Nnochiri "Conjugation-Stabilized Polypeptide Compositions, Therapeutic Delivery and Diagnostic Formulations Comprising Same, and Method of Making and Using the Same" <i>Biotechnology Advances</i> 14(4):575-576 (1996) (Abstract).	
	Engel et al. "Insulin: Intestinal Absorption as Water-in-Oil-in-Water Emulsions" <i>Nature</i> 219:856-857 (1968).	
	Fasano, Alessio "Innovative strategies for the oral delivery of drugs and peptides" <i>TIBTECH</i> 16:152-157 (1998).	
	Forst et al. "New Aspects on Biological Activity of C-peptide in IDDM Patients" <i>Exp. Clin. Endocrinol. Diabetes</i> 106:270-276 (1998).	
	Gish et al. "Nucleic Acids. II. Synthesis of 5'-Esters of 1-13-D-Arabinofuranosylcytosine Possessing Antileukemic and Immuno suppressive Activity" <i>J. Med. Chem.</i> 14(12): 1159- 1162 (1971).	
	Gombotz & Pettit "Biodegradable Polymers for Protein and Peptide Drug Delivery" <i>Bioconjugate Chem.</i> 6:332-351 (1995).	
	Hashimoto et al. "Synthesis of Palmitoyl Derivatives of Insulin and Their Biological Activities" <i>Pharmaceutical Research</i> 6(2):171-176 (1989).	
	Hong et al. "Nucleoside Conjugates. 7. Synthesis and Antitumor Activity of 1-13-D-Arabinofuranosylcytosine Conjugates of Ether Lipids" <i>J. Med Chem.</i> 29:2038-2044 (1986).	
	Hostetler et al. "Synthesis and Antiretroviral Activity of Phospholipid Analogs of Azidothymidine and Other Antiviral Nucleosides" <i>The Journal of Biological Chemistry</i> 265(11):61126117 (1990).	
	Igarashi et al. "Biologically Active Peptides Conjugated with Lecithin for DDS" <i>Proceed. Intern. Symp. Cont. Rd. Bioactiv. Mater</i> 17:367-368 (1990).	
	Kemmler et al. "On the Nature and Subcellular Localization of the Proinsulin Converting Enzymes" <i>Federation Proceedings</i> 30(Abstract 924):1210Abs (1971).	
	Kemmler et al. "Studies on the Conversion of Proinsulin to Insulin: I. Conversion in Vitro with Trypsin and Carboxypeptidase B" <i>The Journal of Biological Chemistry</i> 246(22):6786-6791 (1971).	
	King et al. "Preparation of Protein Conjugates with Alkoxypolyethylene Glycols" <i>Int. J. Peptide Protein Res.</i> 16:147155 (1980).	

TRU-676491 v1

/Samuel Liu/

Date Considered

10/25/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.L./

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	10	Attorney Docket Number	014811-487.114
-------	----	------------------------	----------------

		<i>Kipnes et al. "Control of Postprandial Plasma Glucose by an Oral Insulin Product (HIM2) in Patients with Type 2 Diabetes" Emerging Treatments and Technologies 26:2 (2003).</i>	
		<i>Kipnes et al. "The Effects of an Oral Modified Insulin on Postprandial Blood Glucose Levels in Patients with Type 2 Diabetes Mellitus" American Diabetes Association Annual Meeting (Jun. 2001) (Poster).</i>	
		<i>Kipnes et al. "The Effects of an Oral Modified Insulin on Postprandial Blood Glucose Levels in Patients with Type 2 Diabetes" American Diabetes Association Annual Meeting (Jun. 24, 2001) (Abstract).</i>	
		<i>Kube, D.M. "Multitalented Proteins Play a Key Role in Therapeutics" Genomics and Proteomics (Sep. 2002).</i>	
		<i>Maislos et al. "The Source of the Circulating Aggregate of Insulin in Type I Diabetic Patients is Therapeutic Insulin" J. Clin. Invest. 77:717-723 (1986).</i>	
		<i>Marschutz et al. "Oral Peptide Drug Delivery: Polymer-Inhibitor Conjugates Protecting Insulin from Enzymatic Degradation In Vitro" Biomaterials 21:1499-1507 (2000).</i>	
		<i>Musabayane et al. "Orally Administered, Insulin-Loaded Amidated Pectin Hydrogel Beads Sustain Plasma Concentrations of Insulin in Streptozotocin-Diabetic Rats" Journal of Endocrinology 164:1-6 (2000).</i>	
		<i>Nucci et al. "The Therapeutic Value of Poly(ethylene Glycol) Modified Proteins" Ad. Drug. Del. Rev. 6:133-151 (1991).</i>	
		<i>Oka et al. "Enhanced Intestinal Absorption of a Hydrophobic Polymer-Conjugated Protein Drug, Smancs, in an Oily Formulation" Pharm. Res. 7(8):852-855 (1990).</i>	
		<i>Pang, David C. "Bridging Gaps in Drug Discovery and Development" Pharmaceutical Technology 22:82-94 (Nov. 1998).</i>	
		<i>Patel et al. "Oral Administration of Insulin by Encapsulation Within Liposomes" FEBS Lett. 62(1):60-63 (1976).</i>	
		<i>Puskas et al. "Investigation of Chymotrypsin Digestion Profile of Orally Active Insulin Conjugate HIM2" AAPSPharm Sci. 3(3) 2001 (Abstract).</i>	
		<i>Radhakrishnan et al. "Chemical Modification of Insulin with Amphiphilic Polymers Improves Intestinal Delivery," Proceed. Int'l. Symp. Control. Rd. Bioact. Mater 25:124-125(1998) (Abstract).</i>	